Microbiologics

Microbiologics is a provider of microbiology, molecular diagnostics, and virology solutions, offering reference materials and assay services to laboratories and manufacturers worldwide. Founded in 1971 and headquartered in St. Cloud, US, Microbiologics specializes in microbiological products and has operated since its inception without significant pivots in its business strategy. The company has undergone a recapitalization by Granite Equity Partners in March 2008, although financial terms were not disclosed.

The CEO of the company is Brad Goskowicz. Microbiologics specializes in providing a comprehensive range of microbiology, molecular diagnostics, and virology products and services. Their core offerings include biological reference materials, assay services, and consulting tailored for healthcare and life science laboratories, manufacturers, and suppliers globally. Key products include the EZ-Accu Shot™ and EZ-CFU™ series, which deliver precise and efficient controls for microbiological quality control, facilitating ease of use in laboratories that perform qualitative culture-based testing.

The company serves a diverse client base that encompasses laboratories, pharmaceutical firms, and academic institutions primarily in North America, Europe, and Asia, focusing on applications in infectious disease diagnostics, oncology, and antimicrobial drug testing. With over 50 years of experience, Microbiologics emphasizes quality assurance and regulatory compliance in all its product offerings. Microbiologics generates revenue through a business-to-business model, providing specialized products and services that cater to laboratory needs in the microbiological and diagnostic fields. Transactions typically involve direct sales and partnerships with healthcare and research organizations, where clients purchase products such as microbial reference strains and assay controls for quality assurance testing.

The company may offer subscription-based services for ongoing supply and support, enhancing long-term relationships with customers who rely on consistent product quality and availability. Their flagship products, including the EZ-Accu Shot™ and various custom environmental isolate controls, facilitate testing procedures that meet industry standards. The revenue structure is supported by a commitment to quality and reliability, ensuring that clients can trust the products for critical laboratory applications. Microbiologics aims to expand its product line with new microbiology solutions set to be launched in the coming years, though specific release dates have not been disclosed.

The company is also focused on expanding its market presence in Asia and Europe by 2025. The recapitalization by Granite Equity Partners in March 2008 will support these strategic initiatives and the development of new offerings.